Research analysts at Ladenburg Thalmann Financial Services started coverage on shares of AIT Therapeutics Inc (NASDAQ:AITB) in a research report issued on Monday, The Fly reports. The brokerage set a “buy” rating on the stock.

Shares of AIT Therapeutics (AITB) traded up 36.36% on Monday, reaching $7.50. The company had a trading volume of 9,000 shares. AIT Therapeutics has a 1-year low of $5.00 and a 1-year high of $45.00.

ILLEGAL ACTIVITY NOTICE: “AIT Therapeutics Inc (AITB) Coverage Initiated by Analysts at Ladenburg Thalmann Financial Services” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/08/07/ait-therapeutics-inc-aitb-coverage-initiated-by-analysts-at-ladenburg-thalmann-financial-services.html.

AIT Therapeutics Company Profile

AIT Therapeutics, Inc, formerly KokiCare, Inc, is a shell company. The Company is engaged in the discovery and planning phase to develop a real-time, software as a service (SaaS)-based enterprise software application to manage the integration, planning, tracking and management of healthcare assets, which include people, supplies, clinical data, relationships and financial resources of healthcare organizations.

The Fly

Receive News & Ratings for AIT Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIT Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.